Experts agree – the disease is not over. Diseases are again fragmented, because new variations of our immune system are unprepared.
This is according to a study by Canadian and U.S. researchers who found that vaccines produced in people who were vaccinated and / or recovered from COVID-19 before 2022 failed to eliminate the differences flying today.
The study was led by Igor Stagljar, a professor of biology organic matterAt the Donnelly Center for Molecular Biology and Biomolecular, at the Temerty Faculty of Medicine, by Shawn Owen, professor of medicine and pharmacology, at the University of Utah.
Newspaper Environmental communication they published their findings.
The researchers expect the immunological test they have developed to measure immunity in the study participants will be at an important tool to decide who needs encouragement and time, which will help save lives and avoid future setbacks.
“The fact of the matter is, we still don’t know how to get vaccinated,” Stagljar said. “To answer these questions, we need rapid, low-cost and cost-effective tests that specifically measure SARS-CoV-2 anti-viral properties, which prevent infection.”
Several immunization tests have been developed in the last two years. But only a few of those permitted are designed to monitor antibodies, which block the proliferative protein so that it cannot bind its receptor to the cells.
It is important to note the differences, because only a fraction of all SARS-CoV-2 antibodies that are produced during infection are eliminated. And while many vaccines are designed specifically to produce vaccines, the amount of protection they provide is not specified.
“Our method, which we call Neu-SATiN, is accurate, but faster and cheaper than gold standard, and can be adjusted quickly for new variations as they come out,” he said.
Neu-SATiN stands for Neutralization Serological Assay in relation to the splitting of the Nanoluciferase component, and is a new version of SATiN, which monitors the full IgG pool, which they developed last year.
Zhong Yao, chief research officer at the Stagljar laboratory, and Sun Jin Kim, a graduate student at the Owen laboratory, led the development of Neu-SATiN, who were the first authors in the paper.
The first of its kind, the pin test is intensified by a protein extraction technique using a fluorescent luciferase protein from a deep liquid. It measures the potency of a high-potency protein to bind to the human ACE2 receptor, each of which binds to a piece of luciferase. The combination brings the luciferase particles closer together to rebuild the high-density protein, which provides the light source captured by the luminometer equipment. When a patient’s blood sample is added to the mixture, the antibodies that bind to the excess protein, prevent it from contacting ACE2. As a result, luciferase remains short, with a droplet accompanying the light signal. The blockchain and play path can be adjusted to different variations within two weeks by differentiated engineers into increased protein.
The researchers used Neu-SATiN to blood sample Collected from 63 patients with different histories of COVID-19 infection and vaccination up to November 2021. The efficacy of patients was evaluated on the basis of Wuhan strain and variant, Alpha, Beta, Gamma, Delta and Omicron.
“We thought it would be important to keep an eye on people who have been vaccinated to see if they are still safe and how long it will take,” said Owen, who is training for his master’s degree at the Donnelly Center together. and eminent biologist by Professor Molly Shoichet. “But we also want to see if you have been vaccinated against one variant, does it protect you from another? diversity? “
Antibiotics have been found to last for about three to four months when their levels will drop by almost 70 percent regardless of infection or immune status. The immune system, acquired through infection and vaccination, resulted in higher immunization levels at first, but these also declined significantly after four months.
Most strains, infections and / or vaccines provided good protection from previous variants, but not Omicron, or its variants, BA.4 and BA.5.
The data are consistent with those from a recent UK study, which showed that both were neutral vaccine and cellular immunodeficiency, a type of immune system that produces T cells, from either infection, antibiotics, or both, do not provide protection against Omicron seizures. In a surprising turn of events, the British team also found that infection with Omicron enhances immunity from previous strains, but not on Omicron itself, for unknown reasons.
It is important to emphasize that vaccines still provide significant protection against serious diseases and death, Stagljar said. Once again, he added that research by his team and others is taking precautionary measures in the near future to see that most of the BA4 and BA5 mutations may escape the immune response from infectious diseases. them later with Omicron, as confirmed by re-infection.
“There will be new differences in the future for sure,” Stagljar said. “Monitoring and improving prevention of diversity floating will be important and our approach can play an important role in this since it is fast, accurate, cost-effective and cost-effective.”
His lab is already partnering with Canadian vaccine maker Medicago to help assess the quality of their vaccines on Omicron and other brands. Currently, the U of T is in talks to license Neu-SATiN to a company that will upgrade it so that it can be used for population prevention and the pharmaceutical industry to boost immunization.
Experimental Neutralization Virus Test for Immediate Testing 1 Discussion Cleaning 2 Anti-SARS-CoV-2 Activities, Environmental communication (2022). DOI: 10.1038 / s41467-022-31300-9
University of Toronto
hintResearchers have developed an immunosuppressive test to maintain immunity to the SARS-CoV-2 variant (2022, July 1) recovered July 1, 2022 from https://medicalxpress.com/news/2022-07-antibody -track-immunity-sars- cov-variants.html
This document is copyrighted. Apart from any genuine transaction for research or investigation purposes, a section may not be reproduced without written permission. Content is provided for informational purposes only.
Researchers develop antibody test to keep track of immunity to SARS-CoV-2 variants Source link Researchers develop antibody test to keep track of immunity to SARS-CoV-2 variants